All Stories

  1. Peripubertal Changes in Asthma
  2. Reply
  3. Bacterial communities co-develop with respiratory immunity early in life, linking dysbiosis to systemic monocyte signature and wheezing
  4. Machine learning in allergy research: A bibliometric review
  5. Model-based machine learning to understand the progression of asthma through life-course
  6. Patterns of Respiratory Symptoms and Asthma Diagnosis in School‐Age Children: Three Birth Cohorts
  7. Exploring the Temporal Interplay of Allergic Sensitization and Asthma via Graph and Manifold Analysis
  8. Preschool wheeze and asthma endotypes- implications for future therapy
  9. European Respiratory Society Research Seminar on Preventing Pediatric Asthma
  10. Association of urinary eosinophilic protein X at age 3 years and subsequent persistence of wheezing and asthma diagnosis in adolescence
  11. Social inequalities in childhood asthma
  12. Featured Cover
  13. Tracing the path from preschool wheezing to asthma
  14. Whole Exome Sequencing Identifies Epithelial and Immune Dysfunction‐Related Biomarkers in Food Protein‐Induced Enterocolitis Syndrome
  15. Parent's perception of respiratory syncytial virus and subsequent wheezing burden: A multi‐country cross‐sectional survey
  16. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO
  17. Recommendations for asthma monitoring in children.
  18. Component‐specific clusters for diagnosis and prediction of allergic airway diseases
  19. Association between polymorphisms on chromosome 17q12-q21 and rhinovirus-induced interferon responses
  20. Evaluation of measurement errors in the Patient‐Oriented Eczema Measure (POEM) outcome
  21. Component‐resolved diagnosis in childhood and prediction of asthma in early adolescence: A birth cohort study
  22. Understanding progression from pre‐school wheezing to school‐age asthma: Can modern data approaches help?
  23. Phenotype and endotype based treatment of preschool wheeze
  24. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app
  25. Current state and prospects of artificial intelligence in allergy
  26. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
  27. Reply to Beck et al. and to Owora
  28. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis
  29. Evolution of Lung Function within Individuals: Clinical Insights and Data-driven Methods
  30. EAACI guidelines on environmental science in allergic diseases and asthma – Leveraging artificial intelligence and machine learning to develop a causality model in exposomics
  31. Environmental influences on childhood asthma: Allergens
  32. Will Oral Food Challenges Still Be Part of Allergy Care in 10 Years’ Time?
  33. Early childhood wheezing phenotypes and determinants in a South African birth cohort: longitudinal analysis of the Drakenstein Child Health Study
  34. Dog ownership in infancy is protective for persistent wheeze in 17q21 asthma-risk carriers
  35. Integrative transcriptomic analysis in human and mouse model of anaphylaxis identifies gene signatures associated with cell movement, migration and neuroinflammatory signalling
  36. Progenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases
  37. Evolution of Eczema, Wheeze, and Rhinitis from Infancy to Early Adulthood: Four Birth Cohort Studies
  38. A systems immunology approach to investigate cytokine responses to viruses and bacteria and their association with disease
  39. Childhood Asthma Incidence, Early and Persistent Wheeze, and Neighborhood Socioeconomic Factors in the ECHO/CREW Consortium
  40. Distinct airway epithelial immune responses after infection with SARS-CoV-2 compared to H1N1
  41. In vivo bronchial epithelial interferon responses are augmented in asthma on day 4 following experimental rhinovirus infection
  42. Defining the normal range of fractional exhaled nitric oxide in children: one size does not fit all
  43. Data‐driven research on eczema: Systematic characterization of the field and recommendations for the future
  44. Update in Asthma 2021
  45. WAO-ARIA consensus on chronic cough – Part III: Management strategies in primary and cough-specialty care. Updates in COVID-19
  46. Modeling Wheezing Spells Identifies Phenotypes with Different Outcomes and Genetic Associates
  47. Nonlinear effects of environment on childhood asthma susceptibility
  48. Short-chain fatty acid acetate triggers antiviral response mediated by RIG-I in cells from infants with respiratory syncytial virus bronchiolitis
  49. Life-threatening anaphylaxis to peanut — impossible to predict?
  50. Early life inter-kingdom interactions shape the immunological environment of the airways
  51. The Air We Breathe: Respiratory Impact of Indoor Air Quality in Chronic Obstructive Pulmonary Disease
  52. Early‐life predictors and risk factors of peanut allergy, and its association with asthma in later‐life: Population‐based birth cohort study
  53. Considering biomarkers in asthma disease severity
  54. Data-driven research on eczema: systematic characterization of the field and recommendations for the future
  55. Integration of Genomic Risk Scores to Improve the Prediction of Childhood Asthma Diagnosis
  56. The role of growth and nutrition in the early origins of spirometric restriction in adult life: a longitudinal, multicohort, population-based study
  57. Sex differences in innate anti-viral immune responses to respiratory viruses and in their clinical outcomes in a birth cohort study
  58. WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways
  59. WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation — Updates in COVID-19
  60. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
  61. Modelling trajectories of parentally reported and physician‐confirmed atopic dermatitis in a birth cohort study*
  62. Rare variant analysis in eczema identifies exonic variants in DUSP1, NOTCH4 and SLC9A4
  63. Development of childhood asthma prediction models using machine learning approaches
  64. Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study
  65. The change in exhaled nitric oxide in adolescents – a longitudinal cohort study
  66. Recurrent Severe Preschool Wheeze: From Prespecified Diagnostic Labels to Underlying Endotypes
  67. Four subtypes of childhood allergic rhinitis identified by latent class analysis
  68. Biomarkers of the Severity of Honeybee Sting Reactions and the Severity and Threshold of Systemic Adverse Events During Immunotherapy
  69. Atopic dermatitis or eczema? Consequences of ambiguity in disease name for biomedical literature mining
  70. Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank
  71. Childhood CCL18, CXCL10 and CXCL11 levels differentially relate to and predict allergy development
  72. Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort
  73. 247 Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease
  74. Childhood CCL18, CXCL10 and CXCL11 levels differentially relate to and predict allergy development
  75. Development of Childhood Asthma Prediction Models using Machine Learning Approaches
  76. Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort
  77. Machine learning in asthma research: moving toward a more integrated approach
  78. Four subtypes of childhood allergic rhinitis identified by latent class analysis
  79. Acetate Triggers Antiviral Response Mediated by RIG-I in Cells from Infants with Respiratory Syncytial Virus Bronchiolitis
  80. The Montelukast Therapy in Asthmatic Children with and without Food Allergy: Does It Make Any Difference?
  81. Genetics of Asthma and Allergic Diseases
  82. Does death from Covid-19 arise from a multi-step process?
  83. The role of interferons in preschool wheeze
  84. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies
  85. Circulating Chemokine Levels and the Development of Allergic Phenotypes from Infancy to Adolescence: A Population-Based Birth Cohort Study
  86. Asthma and Allergies: From Diagnosis-Based Approach towards Personalised Treatments
  87. Childhood Asthma: Low and Middle-Income Countries Perspective
  88. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort
  89. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort
  90. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries?
  91. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice
  92. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model
  93. Novel loci for childhood body mass index and shared heritability with adult cardiometabolic traits
  94. Connectivity patterns between multiple allergen specific IgE antibodies and their association with severe asthma
  95. Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement
  96. Sex differences in innate anti-viral immune responses to respiratory viruses
  97. Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19
  98. “Asthma” or “Asthma Spectrum Disorder”?
  99. Atopic phenotypes and their implication in the atopic march
  100. Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden
  101. Targeting maternal immune function during pregnancy for asthma prevention in offspring: Harnessing the “farm effect”?
  102. Update in Asthma 2019
  103. Montelukast therapy in asthmatic children with and without food allergy
  104. Progenitor cell-derived basophils: a novel barcoded passive degranulation assay in allergy diagnosis
  105. Update on House Dust Mite Allergen Avoidance Measures for Asthma
  106. Is death from Covid-19 a multistep process?
  107. Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
  108. Toward personalization of asthma treatment according to trigger factors
  109. Is diet partly responsible for differences in COVID-19 death rates between and within countries?
  110. Expression quantitative trait locus fine mapping of the 17q12–21 asthma locus in African American children: a genetic association and gene expression study
  111. Association of bacterial load in drinking water and allergic diseases in childhood
  112. national initiative in data science for health: an evaluation of the UK Farr Institute
  113. Comparative primary paediatric nasal epithelial cell culture differentiation and RSV-induced cytopathogenesis following culture in two commercial media
  114. Early-life inhalant allergen exposure, filaggrin genotype, and the development of sensitization from infancy to adolescence
  115. Interaction between filaggrin mutations and neonatal cat exposure in atopic dermatitis
  116. Allergic Endotypes and Phenotypes of Asthma
  117. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK‐air ® App
  118. Longitudinal trajectories of severe wheeze exacerbations from infancy to school age and their association with early‐life risk factors and late asthma outcomes
  119. Comparative primary paediatric nasal epithelial cell culture differentiation and RSV-induced cytopathogenesis following culture in two commercial media
  120. Differential associations of allergic disease genetic variants with developmental profiles of eczema, wheeze and rhinitis
  121. Toward clinically applicable biomarkers for asthma: An EAACI position paper
  122. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
  123. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases
  124. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
  125. Dust-mite inducing asthma: what advice can be given to patients?
  126. Temporal association of the development of oropharyngeal microbiota with early life wheeze in a population-based birth cohort
  127. Distinguishing Wheezing Phenotypes from Infancy to Adolescence. A Pooled Analysis of Five Birth Cohorts
  128. Does understanding endotypes translate to better asthma management options for all?
  129. Blood Biomarkers of Sensitization and Asthma
  130. Epidemiology of Asthma in Children and Adults
  131. A trans-ancestral meta-analysis of genome-wide association studies reveals loci associated with childhood obesity
  132. Asthma: moving toward a global children's charter
  133. Nocturnal asthma is affected by genetic interactions between RORA and NPSR1
  134. The Early Growth Genetics (EGG) and EArly Genetics and Lifecourse Epidemiology (EAGLE) consortia: design, results and future prospects
  135. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study
  136. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma
  137. Different definitions of atopic dermatitis: Impact on prevalence estimates and associated risk factors
  138. The Syndrome We Agreed to Call Bronchiolitis
  139. Childhood Asthma: Advances Using Machine Learning and Mechanistic Studies
  140. Validation of childhood asthma predictive tools: A systematic review
  141. Individual risk assessment tool for school-age asthma prediction in UK birth cohort
  142. Pubertal height growth and lung function in adolescence and early adulthood
  143. Causes of variability in latent phenotypes of childhood wheeze
  144. Pediatric asthma: An unmet need for more effective, focused treatments
  145. Machine learning to identify pairwise interactions between specific IgE antibodies and their association with asthma: A cross-sectional analysis within a population-based birth cohort
  146. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence
  147. Trajectories of childhood immune development and respiratory health relevant to asthma and allergy
  148. Evolution of IgE responses to multiple allergen components throughout childhood
  149. Classification of Pediatric Asthma: From Phenotype Discovery to Clinical Practice
  150. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
  151. Reply
  152. Vitamin D receptor genotype influences risk of upper respiratory infection
  153. Author Correction: Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis
  154. Mast cell activation test in the diagnosis of allergic disease and anaphylaxis
  155. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis
  156. Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies
  157. Pulmonary epithelial barrier and immunological functions at birth and in early life - key determinants of the development of asthma?  A description of the protocol for the Breathing Together study
  158. Cytokine Responses to Rhinovirus and Development of Asthma, Allergic Sensitization, and Respiratory Infections during Childhood
  159. Development of allergic sensitization and its relevance to paediatric asthma
  160. Important and specific role for basophils in acute allergic reactions
  161. Temperature-controlled laminar airflow (TLA) device in the treatment of children with severe atopic eczema: Open-label, proof-of-concept study
  162. Epistasis between FLG and IL4R Genes on the Risk of Allergic Sensitization: Results from Two Population-Based Birth Cohort Studies
  163. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
  164. Cat ownership, cat allergen exposure, and trajectories of sensitization and asthma throughout childhood
  165. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy
  166. Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force
  167. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study
  168. After asthma: redefining airways diseases
  169. Genome-wide search identifies new genetic variants associated with asthma risk.
  170. Non-parametric mixture models identify trajectories of childhood immune development relevant to asthma and allergy
  171. Predictive Modelling Strategies to Understand Heterogeneous Manifestations of Asthma in Early Life
  172. Detection of IgE Reactivity to a Handful of Allergen Molecules in Early Childhood Predicts Respiratory Allergy in Adolescence
  173. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
  174. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control
  175. Diagnosis of asthma in symptomatic children based on measures of lung function: an analysis of data from a population-based birth cohort study
  176. NIAID, NIEHS, NHLBI, and MCAN Workshop Report: The indoor environment and childhood asthma—implications for home environmental intervention in asthma prevention and management
  177. Features of asthma which provide meaningful insights for understanding the disease heterogeneity
  178. Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis
  179. Shared genetic variants suggest common pathways in allergy and autoimmune diseases
  180. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)
  181. Epigenome-wide analysis links SMAD3 methylation at birth to asthma in children of asthmatic mothers
  182. Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers
  183. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement
  184. Formula one: best is no formula
  185. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
  186. Disaggregating asthma: Big investigation versus big data
  187. Epidemiology of Allergic Diseases
  188. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem
  189. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
  190. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies
  191. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA
  192. Allergy in severe asthma
  193. Asthma phenotypes in childhood
  194. The importance of being earnest in epidemiology
  195. Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA
  196. A new framework for the interpretation of IgE sensitization tests
  197. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
  198. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
  199. AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation
  200. Treatment of asthma in young children: evidence-based recommendations
  201. Insoluble and soluble roasted walnut proteins retain antibody reactivity
  202. Age, sex and the association between skin test responses and IgE titres with asthma
  203. Distinguishing benign from pathologic TH2 immunity in atopic children
  204. Evolution pathways of IgE responses to grass and mite allergens throughout childhood
  205. Genome-wide association analysis identifies three new susceptibility loci for childhood body mass index
  206. Relationship between cytokine expression patterns and clinical outcomes: two population‐based birth cohorts
  207. Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years
  208. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis
  209. Atopic Dermatitis and Respiratory Allergy: What is the Link
  210. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation
  211. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study
  212. Distinguishing Asthma Phenotypes Using Machine Learning Approaches
  213. The Study Team for Early Life Asthma Research (STELAR) consortium ‘Asthma e-lab’: team science bringing data, methods and investigators together: Figure 1
  214. To what extent is allergen exposure a risk factor for the development of allergic disease?
  215. Developmental Profiles of Eczema, Wheeze, and Rhinitis: Two Population-Based Birth Cohort Studies
  216. A multicentre study of air pollution exposure and childhood asthma prevalence: the ESCAPE project
  217. A novel common variant in DCST2 is associated with length in early life and height in adulthood
  218. Peanut allergy: Effect of environmental peanut exposure in children with filaggrin loss-of-function mutations
  219. Polymorphisms of endotoxin pathway and endotoxin exposure:in vitroIgE synthesis and replication in a birth cohort
  220. Elemental Composition of Particulate Matter and the Association with Lung Function
  221. Cross-sectional association of dietary patterns with asthma and atopic sensitisation in childhood - in a cohort study
  222. Impact of rhinitis on asthma severity in school-age children
  223. Assessing the association of early life antibiotic prescription with asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: a population-based birth cohort study
  224. Fraction of exhaled nitric oxide values in childhood are associated with 17q11.2-q12 and 17q12-q21 variants
  225. Integrated care pathways for airway diseases (AIRWAYS-ICPs)
  226. Effect of a novel temperature-controlled laminar airflow device on personal breathing zone aeroallergen exposure
  227. Genetic variants in endotoxin signalling pathway, domestic endotoxin exposure and asthma exacerbations
  228. Trajectories of Lung Function during Childhood
  229. Challenges in Interpreting Wheeze Phenotypes: The Clinical Implications of Statistical Learning Techniques
  230. Predicting phenotypes of asthma and eczema with machine learning
  231. Allergen Control for Prevention and Management of Allergic Diseases
  232. Challenges in Identifying Asthma Subgroups Using Unsupervised Statistical Learning Techniques
  233. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations
  234. EAACI position statement on asthma exacerbations and severe asthma
  235. Air Pollution Exposure and Lung Function in Children: The ESCAPE Project
  236. Differing associations of BMI and body fat with asthma and lung function in children
  237. Challenges in interpreting allergen microarrays in relation to clinical symptoms: A machine learning approach
  238. Characterizing wheeze phenotypes to identify endotypes of childhood asthma, and the implications for future management
  239. Long-term Exposure to PM 10 and NO 2 in Association with Lung Volume and Airway Resistance in the MAAS Birth Cohort
  240. Effects of long-term exposure to PM10and NO2on asthma and wheeze in a prospective birth cohort
  241. Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing
  242. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology
  243. Breath metabolomic profiling by nuclear magnetic resonance spectroscopy in asthma
  244. Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization
  245. Interaction betweenglutathione S-transferasevariants, maternal smoking and childhood wheezing changes with age
  246. 17q12-21 and asthma: interactions with early-life environmental exposures
  247. Multiple atopy phenotypes and their associations with asthma: similar findings from two birth cohorts
  248. Pediatric asthma and development of atopy
  249. Methylation ofIL-2promoter at birth alters the risk of asthma exacerbations during childhood
  250. Asthma severity, polymorphisms in 20p13 and their interaction with tobacco smoke exposure
  251. Pooling Birth Cohorts in Allergy and Asthma: European Union-Funded Initiatives – A MeDALL, CHICOS, ENRIECO, and GA<sup>2</sup>LEN Joint Paper
  252. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
  253. Food protein–induced enterocolitis syndrome can occur in adults
  254. Does Pet Ownership in Infancy Lead to Asthma or Allergy at School Age? Pooled Analysis of Individual Participant Data from 11 European Birth Cohorts
  255. International consensus on (ICON) pediatric asthma
  256. Infantile and preschool asthma
  257. 17q12-21 Variants are associated with asthma and interact with active smoking in an adult population from the United Kingdom
  258. Gene–environment interactions in the development of asthma and atopy
  259. Genetic Variation in Vascular Endothelial Growth Factor-A and Lung Function
  260. Lung development and the role of asthma and allergy
  261. Estimated portion sizes in a school-aged population
  262. Erratum
  263. Davos Declaration: Allergy as a global problem
  264. Research needs in allergy: an EAACI position paper, in collaboration with EFA
  265. Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA<sup>2</sup>LEN – ARIA Position Paper
  266. The CREATE Project: Development of Certified Reference Materials for Allergenic Products and Validation of Methods for Their Quantification
  267. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis
  268. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years
  269. Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen–Induced Allergic Rhinoconjunctivitis
  270. Differences in both prevalence and titre of specific immunoglobulin E among children with asthma in affluent and poor communities within a large town in Ghana
  271. Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood
  272. Molecular diagnosis of peanut and legume allergy
  273. Peanut allergy: Overestimated in epidemiology or underdiagnosed in primary care?
  274. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy
  275. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
  276. Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies
  277. Response
  278. Quantification of atopy, lung function and airway hypersensitivity in adults
  279. Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper
  280. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
  281. Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma
  282. Allergy is an important factor in asthma exacerbation: A Pro/Con Debate
  283. Increased serum-soluble interleukin-5 receptor alpha level precedes the development of eczema in children
  284. Body mass index in young children and allergic disease: gender differences in a longitudinal study
  285. Beyond Atopy
  286. Changes in the FEV1/FVC ratio during childhood and adolescence: an intercontinental study
  287. Reference equations for specific airway resistance in children: the Asthma UK initiative
  288. Allergy or tolerance in children sensitized to peanut: Prevalence and differentiation using component-resolved diagnostics
  289. Dietary antioxidant intake, allergic sensitization and allergic diseases in young children
  290. Unmet needs in severe chronic upper airway disease (SCUAD)
  291. Prevention of allergic sensitization by environmental control
  292. Spirometry Centile Charts for Young Caucasian Children: The Asthma UK Collaborative Initiative
  293. Allergen Avoidance
  294. Long-Term Effects of Allergen Sensitization and Exposure in Adult Asthma
  295. Immune System Modeling with Infer.NET
  296. The European Union CREATE Project: A model for international standardization of allergy diagnostics and vaccines
  297. Day-care attendance, position in sibship, and early childhood wheezing: A population-based birth cohort study
  298. Early identification of atopy in the prediction of persistent asthma in children
  299. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper
  300. Gene-Environment Interaction in the Onset of Eczema in Infancy: Filaggrin Loss-of-Function Mutations Enhanced by Neonatal Cat Exposure
  301. Dimensions of Respiratory Symptoms in Preschool Children
  302. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach
  303. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
  304. EU Forum: The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantification
  305. Bifidobacterium pseudocatenulatum is associated with atopic eczema: A nested case-control study investigating the fecal microbiota of infants
  306. Management of the asthmatic patient
  307. Quantification of atopy and the probability of rhinitis in preschool children: a population-based birth cohort study
  308. Two blind mice: New insights into mouse allergy
  309. Staphylococcus aureus sensitization and allergic disease in early childhood: Population-based birth cohort study
  310. Original article: Rhinoconjunctivitis in 5-year-old children: a population-based birth cohort study
  311. Active smoking among asthmatic youth?How concerned we need to be
  312. Exercise-Induced Bronchospasm and Atopy in Ghana: Two Surveys Ten Years Apart
  313. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)
  314. European birth cohort studies on asthma and atopic diseases: II. Comparison of outcomes and exposures – a GA2LEN initiative
  315. Endotoxin Exposure, CD14, and Allergic Disease
  316. Exhaled Breath Condensate pH and Childhood Asthma
  317. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study
  318. Allergen avoidance in the secondary and tertiary prevention of allergic diseases: does it work?
  319. Atopic wheezing and early life antibiotic exposure: a nested case-control study
  320. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children
  321. Dietary intake in sensitized children with recurrent wheeze and healthy controls: a nested case-control study
  322. Environmental exposures, genetic predisposition and allergic diseases: one size never fits all
  323. Intranasal air sampling in homes: Relationships among reservoir allergen concentrations and asthma severity
  324. Domestic allergen and endotoxin exposure and allergic sensitization in Cyprus
  325. Drugs used in paediatric allergy: should we conduct studies in children or extrapolate from adults?
  326. European birth cohort studies on asthma and atopic diseases: I. Comparison of study designs - a GA2LEN initiative
  327. Epidemiology of Allergic Disease
  328. Fungal contamination of bedding
  329. High-efficiency vacuum cleaners increase personal mite allergen exposure, but only slightly
  330. What are we learning from genetic cohort studies?
  331. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization
  332. IgE antibody quantification and the probability of wheeze in preschool children
  333. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA2LEN)
  334. Polymorphisms in A Disintegrin and Metalloprotease 33 ( ADAM33 ) Predict Impaired Early-Life Lung Function
  335. The information needs and preferred roles in treatment decision-making of parents caring for infants with atopic dermatitis: a qualitative study
  336. The role of allergen avoidance in the secondary prevention of atopic disorders
  337. Fecal microbiota in sensitized wheezy and non-sensitized non-wheezy children: a nested case-control study
  338. Pets and the development of allergic sensitization
  339. Potential roles in rhinitis for protease and other enzymatic activities of allergens
  340. Allergy and infection: understanding their relationship
  341. Effect of Mycobacterium vaccae on cytokine responses in children with atopic dermatitis
  342. Behavior Problems Antecede the Development of Wheeze in Childhood
  343. Wheeze Phenotypes and Lung Function in Preschool Children
  344. Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitised, atopic asthmatic subjects
  345. Asthma and sensitization in a community with low indoor allergen levels and low pet-keeping frequency
  346. Environmental allergen exposure, sensitisation and asthma: from whole populations to individuals at risk
  347. Lung Function at Age 3 Years
  348. World Allergy Organization Guidelines for Prevention of Allergy and Allergic Asthma
  349. Early Life Environmental Control
  350. Dampness in buildings as a risk factor for health effects, EUROEXPO: a multidisciplinary review of the literature (1998-2000) on dampness and mite exposure in buildings and health effects
  351. Response to ‘No clinical evidence base to support the hygiene hypothesis’ by C. P. van Schayck and J. A. Knottnerus
  352. No clinical evidence base to support the hygiene hypothesis
  353. Protective parasites and medicinal microbes? The case for the hygiene hypothesis
  354. Reported versus confirmed wheeze and lung function in early life
  355. Allergens, Viruses, and Asthma Exacerbations
  356. Childhood asthma
  357. Allergen avoidance in the primary prevention of asthma
  358. Can we prevent allergy?
  359. World Allergy Organization Guidelines for Prevention of Allergy and Allergic Asthma
  360. Manchester cohort
  361. The role of allergen avoidance in primary and secondary prevention
  362. Tobacco smoke exposure, wheeze, and atopy
  363. Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients
  364. Urinary eosinophilic protein X, atopy, and symptoms suggestive of allergic disease at 3 years of age
  365. Primary and secondary prevention of allergic airway disease
  366. Stringent environmental control in pregnancy and early life: the long-term effects on mite, cat and dog allergen
  367. Childhood asthma, behavior problems, and family functioning
  368. Endotoxin contamination contributes to the pulmonary inflammatory and functional response to Aspergillus fumigatus extract inhalation in heaves horses
  369. Exposure and sensitization to indoor allergens: Association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma
  370. Control of Exposure to Mite Allergen and Allergen-Impermeable Bed Covers for Adults with Asthma
  371. Air filtration units in homes with cats: can they reduce personal exposure to cat allergen?
  372. High-efficiency particulate arrest–filter vacuum cleaners increase personal cat allergen exposure in homes with cats
  373. Childhood asthma
  374. Current mite, cat, and dog allergen exposure, pet ownership, and sensitization to inhalant allergens in adults
  375. Early pet exposure: friend or foe?
  376. Clinical effects of air filters in homes of asthmatic adults sensitized and exposed to pet allergens
  377. Skin test reactivity to natural and recombinant Blomia and Dermatophagoides spp. allergens among mite allergic patients in the UK
  378. The National Asthma Campaign Manchester Asthma and Allergy Study
  379. Clostridium difficile , atopy and wheeze during the first year of life
  380. Household characteristics and mite allergen levels in Manchester,UK
  381. The effect of allergen exposure in early childhood on the development of atopy
  382. Preventive measures and their effects
  383. Seasonal variability in exercise test responses in Ghana
  384. Specific airway resistance in 3-year-old children: a prospective cohort study
  385. Personal exposure to house dust mite allergen in bed: nasal air sampling and reservoir allergen levels
  386. Controlling indoor allergens
  387. Is allergen avoidance effective?*
  388. Lung function at one month of age as a risk factor for infant respiratory symptoms in a high risk population
  389. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study
  390. Array-based diagnostic gene-expression score for atopy and asthma
  391. Environmental allergens in Kuwait
  392. Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study
  393. Decreased prevalence of sensitization to cats with high exposure to cat allergen
  394. The role of indoor allergen exposure in the development of sensitization and asthma
  395. The role of indoor allergen exposure in the development of sensitization and asthma
  396. Pet allergen levels in homes in Ghana and the United Kingdom
  397. Risk factors for asthma in urban Ghana
  398. Avoidance of allergens and air pollutants in respiratory allergy
  399. Lymphoproliferative responses in cord blood and at one year: no evidence for the effect of in utero exposure to dust mite allergens
  400. Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomised trial
  401. Housing characteristics and mite allergen levels: to humidity and beyond
  402. On allergens and asthma (again): does exposure to allergens in homes exacerbate asthma?
  403. Exposure and sensitization in infants and children
  404. Exposure and sensitization in infants and children
  405. NAC Manchester Asthma and Allergy Study (NAC MAAS): risk factors for asthma and allergic disorders in adults
  406. Apoptosis signals in atopy and asthma measured with cDNA arrays
  407. Environmental allergen exposure and asthma: prospects for primary prevention
  408. The −403 G→A promoter polymorphism in the RANTES gene is associated with atopy and asthma
  409. Chapter 1: Genetic and Environmental Influences
  410. Prevention of Allergy and Asthma
Interim Report
  411. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study
  412. Synthetic pillows contain higher levels of cat and dog allergen than feather pillows
  413. Manchester Asthma and Allergy Study: Low-allergen environment can be achieved and maintained during pregnancy and in early life
  414. Clinical Effects of Allergen Avoidance
  415. Allergen avoidance: does it work?
  416. Dust mite allergens are carried on not only large particles
  417. Exhaled Nitric Oxide, Sensitization, and Exposure to Allergens in Patients with Asthma Who Are Not Taking Inhaled Steroids
  418. Relationship between mite, cat, and dog allergens in reservoir dust and ambient air
  419. Attempting to control mite allergens with mechanical ventilation and dehumidification in British houses
  420. The effect of air filtration on airborne dog allergen
  421. Mite allergens in feather and synthetic pillows
  422. Vacuum cleaners and airborne dog allergen
  423. Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week
  424. Sensitivity and exposure to indoor allergens in adults with differing asthma severity
  425. Feather or synthetic? That is the question
  426. The effect of dry heat on mite, cat, and dog allergens
  427. Importance of indoor allergens in the induction of allergy and elicitation of
  428. Risk levels for mite allergens. Are they meaningful?
  429. Indoor environmental factors and respiratory illness
  430. Role of the indoor environment in determining the severity of asthma
  431. Variability of house-dust-mite allergen levels within carpets
  432. ABC of allergies: Avoiding exposure to indoor allergens
  433. Allergen avoidance in the treatment of asthma and atopic disorders
  434. Distribution, aerodynamic characteristics, and removal of the major cat allergen Fel d 1 in British homes
  435. Domestic allergens in public places III: house dust mite, cat, dog and cockroach allergens in British hospitals
  436. Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren
  437. Aerodynamic properties of the major dog allergen Can f 1: distribution in homes, concentration, and particle size of allergen in the air.
  438. Domestic allergens in public places II: dog (Can f 1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings
  439. New mattresses: how fast do they become a significant source of exposure to house dust mite allergens?
  440. Domestic allergens in public places II: dog (Can f 1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings
  441. New mattresses: how fast do they become a significant source of exposure to house dust mite allergens?
  442. Reduction in humidity as a method of controlling mites and mite allergens: the use of mechanical ventilation in British domestic dwellings
  443. Reduction in humidity as a method of controlling mites and mite allergens: the use of mechanical ventilation in British domestic dwellings
  444. Exposure to house dust mite allergens and the clinical activity of asthma
  445. Asthmatic bronchial hyperresponsiveness varies with ambient levels of summertime air pollution
  446. Evaluating exposure to mite allergens
  447. GR106642X: a new, non-ozone depleting propellant for inhalers
  448. Portable dehumidifiers in the control of house dust mites and mite allergens
  449. House dust mite and cat allergen in different indoor environments
  450. Assessing Exercise-induced Bronchospasm
  451. Exercise Testing Revisited
  452. Animal Allergens
  453. Does Allergen Avoidance Help? What are the Practical Measures that Patients can Take?